Harsh Criticism for Attorneys in Lupron Class Action

In the litigation over alleged illegal pricing tactics used in marketing the prostate cancer drug Lupron, the fate of hundreds of plaintiffs remains unclear despite a federal judge's approval earlier this month of $150 million in settlements.

And complicating the claims of nearly all of the so-called "opt-out" plaintiffs is the fact that their lawyers at the Philadelphia firm Kline & Specter were harshly criticized by the judge for their marketing tactics.

In his May 12 decision, U.S. District Judge Richard G. Stearns of the District of Massachusetts faulted Kline & Specter for launching a pair of Internet Web sites that, Stearns said, were "intended to mislead potential members of the [federal multi-district litigation] MDL class."

It gets much worse than that -- especially toward the end of the article. Details here from The Legal Intelligencer via Law.com.